Hospital outpatient pharmacy leaders cite staffing shortages, managing multiple vendors, and navigating insurer red tape—specialty drug referrals and prior authorization requirements, specifically—among top workplace challenges, a new survey finds. As 340B providers continue to grapple with pharmaceutical manufacturer contract pharmacy
…
Prescription drugs sales at 340B prices were $38.8 billion in 2020, “more than three times the level of 340B sales compared to just five years prior,” new drug industry funded research shows.
Total sales would have been $93.6 billion if
…
340B contract pharmacy grew in affluent and White neighborhoods from 2011 to 2019 but declined in impoverished, Black, and Latino neighborhoods, raising questions about “the degree to which 340B program growth serves vulnerable communities,” according to research published this morning
…
The National Association of Community Health Centers urged Congress and the Biden administration this afternoon to force drug companies to ship 340B drugs to contract pharmacies unconditionally and stop pharmacy benefit managers from siphoning off health centers’ 340B savings.
NACHC
…
Many 340B hospitals “may not offer low-income patients financial assistance to access medicines and may use extraordinary collection actions, including but not limited to, liens, foreclosures, and civil actions when patients fail to pay bills,” a pharmaceutical-industry funded study released
…
One-third (33%) of community health center (CHC) senior executives whose organizations do not currently have an on-site pharmacy plan to open one in the next three years, a new survey shows.
340B pharmacy management company Maxor 340B released the survey
…
The U.S. uninsured rate fell slightly in 2021 to 9.2% (about 30 million people), down from 9.7% (about 31.6 million people) in 2020, the National Center for Health Statistics (NCHS) reports.
NCHS released this and related health insurance coverage findings earlier
…
An American Action Forum (AAF) data analysis that connects increases in consumer drug spending with the introduction of 340B drug discount and Medicaid drug rebate program policies “is spurious at best,” says an expert on prescription drug costs whose research
…
The financial impact to 340B hospitals due to drug manufacturers’ restrictions on contract pharmacy more than doubled between December 2021 and March 2022, a new survey shows.
Hospital trade group 340B Health said the median annualized loss of contract pharmacy
…*Sign up for news summaries and alerts from 340B Report